Volcano Corporation (Volcano) designs, develops, manufactures and commercializes a range of precision guided therapy tools, including intravascular ultrasound (IVUS), and fractional flow reserve (FFR), products. The Company is facilitating the adoption of functional percutaneous interventional (PCI), in which its FFR technology is used to determine whether or not a stent is necessary, and IVUS is used to guide stent placement and optimization. It markets its products to physicians and technicians who perform PCI procedures in hospitals and to other personnel who make purchasing decisions on behalf of hospitals. Its products consist of multi-modality consoles, which are marketed as stand-alone units or as customized units that can be integrated into a range of hospital-based interventional surgical suites called catheterization laboratories (cath labs). In June 2014, Volcano Corp acquired the entire share capital of AtheroMed Inc.